BioSpace News Archive

Business

Signs of Trouble Emerge as Sio Gene Halts UMass Gangliosidosis Deal

Sio Gene has terminated its licensing deal with the UMass to develop and commercialize two gene therapy product candidates to focus on more potentially profitable projects.

April 28, 2022
·
2 min read
·
Vanessa Doctor, RN
Merck Makes Waves in Q1 with COVID-19 Treatment, Cancer Portfolio

Merck held a conference call Thursday morning to discuss its Q1 2022 earnings. The company reported a 50% growth in revenue, increasing its worldwide sales to $15.9 billion.

April 28, 2022
·
2 min read
·
Hayley Shasteen
Drug Development

AstraZeneca’s Alexion Scores Third FDA Approval For Ultomiris

Alexion shared the news that Ultomiris (ravulizumab-cwvz) has been approved by the FDA for commercialization, adding another indication for the precedent-setting drug.

April 28, 2022
·
3 min read
·
Jazmine Colatriano
Business

Lilly Touts Obesity Drug, COVID-19 Antibodies in Upbeat Quarterly Report

Eli Lilly had a lucrative first quarter, with revenue growth rising 15% driven by sales of its diabetes drug Trulicity and its COVID-19 antibodies.

April 28, 2022
·
3 min read
·
Mark Terry
Sanofi-Backed OMass Therapeutics Rakes in $100M to Drug the “Undruggable”

Oxford, UK-based OMass Therapeutics closed on a $100 million Series B financing round. The round was led by new investors GV (formerly Google Ventures), Northpond Ventures and Sanofi Ventures. Three existing investors also participated: Syncona, Oxford Science Enterprise and Oxford University.

April 28, 2022
·
3 min read
·
Mark Terry
Drug Development

Pfizer DMD Trial Moves Forward After FDA Lifts Hold

Pfizer says it will open the first U.S. sites in its Phase III study evaluating its investigational mini-dystrophin gene therapy in ambulatory patients with Duchenne muscular dystrophy (DMD).

April 28, 2022
·
2 min read
·
Geoff Herman
Drug Development

Moderna Makes Official Ask for Young Kids’ Vaccine, Introduces Montreal mRNA Facility

Moderna has made the official request to the FDA to approve its COVID-19 for use in children ages 6 months to 5 years. Moderna also announced the location of its first non-U.S. mRNA manufacturing facility.

April 28, 2022
·
2 min read
·
Mark Terry
Business

Kelonia Scores $50M to Propel In Vivo Gene Delivery Platform

Boston-based Kelonia Therapeutics launched after a successful $50 million Series A round of financing, which will push its research efforts in genetic medicines for immunology and oncology.

April 28, 2022
·
3 min read
·
Hannah Chudleigh
Business

Allogene, Progenity, Adaptive Phage Tout New Top Executives

Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.

April 28, 2022
·
8 min read
·
Alex Keown
The Doctor Will Smell You Now: The Rise of AI-Olfaction in Healthcare

Researchers from Zhejiang University in China developed an artificially intelligent olfactory system for the diagnosis of Parkinson’s disease. An “e-nose” was built to “smell” samples from patients.

April 28, 2022
·
5 min read
·
Hayley Shasteen